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When Glycoprotein IIb/IIIa Inhibitors
Are Not Used?
Michael S. Lee, MD,* Seung-Woon Rha, MD,y Kyung Woo Park, MD,z Moo Hyun Kim, MDxT he relationship between bleeding complica-tions and increased mortality after percuta-neous coronary intervention (PCI) has been
well documented. Bivalirudin is superior to heparin
and glycoprotein (GP) IIb/IIIa inhibitors, mainly due
to the lower risk of bleeding but comparable rates of
ischemic complications (1–3). Three trials presented
at the 2014 American College of Cardiology Scientiﬁc
Sessions raise questions regarding the superiority of
bivalirudin in PCI (4–6).
In the HEAT-PPCI (Unfractionated Heparin Versus
Bivalirudin in Primary Percutaneous Coronary Inter-
vention) trial, 1,829 patients from a single center with
ST-segment elevation myocardial infarction (STEMI)
referred for primary PCI were randomized to heparin
(70 U/kg bolus) or bivalirudin, with GP IIb/IIIa inhib-
itor only used for bail out (15.5% vs. 13.5%, p ¼ NS)
(4). The majority of the PCI (>80%) were performed
transradially. Nearly all patients (99.6%) were pre-
loaded with dual antiplatelet therapy; 60% of pa-
tients received ticagrelor and 27% received prasugrel.
The primary efﬁcacy endpoint of major adverse car-
diac events at 4 weeks, deﬁned as all-cause mortality,
cerebrovascular accident, reinfarction, or unplanned
target lesion revascularization, was lower in the
heparin group (5.7% vs. 8.7%; relative risk [RR]: 1.52,
95% conﬁdence interval [CI]: 1.1 to 2.1, p ¼ 0.01),
which was driven by less reinfarction and target
lesion revascularization without any increase in
bleeding complications (3.1% vs. 3.5%, p ¼ 0.59).
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Ethical concerns were raised as informed consent was
obtained after PCI in those who survived.
In the BRAVE (Bavarian Reperfusion Alternatives
Evaluation)-4 trial, 548 patients with ST-segment
elevation myocardial infarction who underwent
transfemoral PCI (except for 1 patient) were ran-
domized to either: 1) a prasugrel 60-mg loading dose
plus bivalirudin; or 2) heparin (70- to 100-IU/kg bolus)
plus a clopidogrel 600-mg loading dose (5). Bailout GP
IIb/IIIa inhibitors were used in 3% of the prasugrel/
bivalirudin group and 6% of the clopidogrel/heparin
group. Unfortunately, the trial was terminated early
due to slow recruitment, which, therefore, limits our
ability to make deﬁnitive conclusions. The primary
composite endpoint of all-cause death, recurrent
myocardial infarction, unplanned revascularization
of the infarct-related artery, deﬁnite stent throm-
bosis, stroke, or major bleeding at 30 days was
similar in the prasugrel/bivalirudin group compared
with the clopidogrel/heparin group, as was non–cor-
onary artery bypass grafting–related bleeding and
mortality.
In the NAPLES (Novel Approaches in Preventing or
Limiting Events) III trial, 837 patients undergoing
elective transfemoral (99.5%) PCI deemed to be at
high risk for bleeding complications were randomized
to bivalirudin or heparin (70 U/kg bolus followed by
20 U/kg to maintain an activated clotting time above
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224bleeding was similar between the bivalirudin and
heparin groups. At 30 days, clinical endpoints were
also similar: major adverse cardiac events, death,
myocardial infarction, stent thrombosis, and major
bleeding. Bailout use of GP IIb/IIIa inhibitor was un-
common in both groups.
Previous studies suggested a possible increased
risk of ischemic complications with bivalirudin. In
the HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stent in Acute Myocardial
Infarction) trial, patients treated with bivalirudin had
an increased risk of acute stent thrombosis (1.3% vs.
0.3%, p < 0.001). The 1-year mortality rate was lower
in patients treated with bivalirudin compared with
heparin and GP IIb/IIIa inhibitor (3.5% vs. 4.8%,
p ¼ 0.037), which might possibly be explained by the
increased bleeding rate with GP IIb/IIIa inhibitors (3).
In the ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trial, patients treated
with bivalirudin that were not pre-treated with dual
antiplatelet therapy had increased ischemic compli-
cations compared with those treated with heparin
and GP IIb/IIIa inhibitor (9.1% vs. 7.1%, RR: 1.29, 95%
CI: 1.03 to 1.63) (2).
In elective PCI, the REPLACE (Randomized Evalu-
ation in PCI Linking Angiomax to Reduced ClinicalEvents)-2 trial demonstrated that bivalirudin was not
inferior to heparin and GP IIb/IIIa inhibitors in terms
of suppression of acute ischemic endpoints but was
associated with less bleeding (1). However, the use of
GP IIb/IIIa inhibitors is rare in elective PCI.
Assessing the safety and efﬁcacy of antico-
agulation on such a dynamic landscape is clearly a
challenge. Three recent trials suggest that, when a
GP IIb/IIIa inhibitor is selectively used, heparin, if
dosed appropriately, is a cost-effective antith-
rombotic agent for PCI when patients are pre-loaded
with dual antiplatelet therapy, with signiﬁcant cost
savings. The higher risk of bleeding observed in the
previous trials may be attributed to high doses of
heparin and the use of GP IIb/IIIa inhibitors,
although its current use is infrequent and limited to
a small, high-risk group with heavy thrombotic
burden. Further studies are needed to determine
the optimal antithrombotic and antiplatelet regi-
mens that provide the least bleeding and ischemic
complications.
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